abt-639
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2011 (NCT01345045)
Timeline
2010s
- Jan 1, 2011
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
Voltage-gated T-type calcium channel alpha-1H subunit blocker
- Voltage-gated T-type calcium channelINHIBITOR
Voltage-gated T-type calcium channel inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=C(c1cc(S(=O)(=O)Nc2ccccc2F)c(F)cc1Cl)N1CCN2CCC[C@@H]2C1- Mol. weight
- 455.91 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3590674 ↗
Also known as
- 4-chloro-2-fluoro-n-(2-fluorophenyl)-5-(hexahydropyrrolo(1,2-a)pyrazin-2(1h)-ylcarbonyl)benzenesulfonamide
- abt-639
- abt-639
- abt-639
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01589432 | Phase 2 | Apr 1, 2012 | AbbVie |
| NCT01345045 | Phase 2 | Apr 1, 2011 | AbbVie |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AbbVie | For profit | 2 | 2 | 1 | 2011 |
1 organizations
Page 1 / 1